Keywords: update, merck, co, emend, gets, backing, fda

Update: Merck & Co's Emend gets backing from FDA advisory panel

Article | 17 March 2003

Print This

Merck & Co's new drug for the prevention of nausea and vomiting inpatients undergoing chemotherapy for cancer, Emend (aprepitant), has won ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in